Analyzing Molecular Partners (NASDAQ:MOLN) & Incyte (NASDAQ:INCY)

Incyte (NASDAQ:INCY) and Molecular Partners (NASDAQ:MOLN) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, profitability, institutional ownership, dividends and valuation.

Valuation and Earnings

This table compares Incyte and Molecular Partners”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14 billion	4.47	$1.29 billion	$7.85	14.43
Molecular Partners	N/A	N/A	-$74.41 million	($1.71)	-2.19

Incyte has higher revenue and earnings than Molecular Partners. Molecular Partners is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

97.0% of Incyte shares are held by institutional investors. Comparatively, 26.5% of Molecular Partners shares are held by institutional investors. 16.2% of Incyte shares are held by company insiders. Comparatively, 5.9% of Molecular Partners shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Incyte and Molecular Partners’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Incyte	27.71%	29.93%	22.88%
Molecular Partners	N/A	-68.36%	-54.82%

Analyst Ratings

This is a summary of current ratings and recommmendations for Incyte and Molecular Partners, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0	13	11	1	2.52
Molecular Partners	1	1	2	0	2.25

Incyte presently has a consensus price target of $128.20, indicating a potential upside of 13.18%. Molecular Partners has a consensus price target of $8.38, indicating a potential upside of 123.63%. Given Molecular Partners’ higher possible upside, analysts plainly believe Molecular Partners is more favorable than Incyte.

Risk and Volatility

Incyte has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. Comparatively, Molecular Partners has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500.

Summary

Incyte beats Molecular Partners on 12 of the 14 factors compared between the two stocks.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

About Molecular Partners

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.